XC007
/ Xcowery Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 27, 2025
Preclinical Profile of XC007: A Next-Generation PD-1/VEGF Bispecific Antibody Designed for Enhanced Efficacy and Subcutaneous Delivery [WITHDRAWN]
(ESMO-IO 2025)
- No abstract available
Preclinical • Oncology • PD-1
1 to 1
Of
1
Go to page
1